Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Part C: RM-718 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| RM-718 (Cohort A1) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort A2) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort A3) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort A4) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort A5) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort A6) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort A7) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort A8) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort A9) | EXPERIMENTAL | Single dose of RM-718 (4) or placebo (2) |
| RM-718 (Cohort B1) | EXPERIMENTAL | Multiple ascending doses of RM-718 (4) or placebo (2) |
| RM-718 (Cohort B2) | EXPERIMENTAL | Multiple ascending doses of RM-718 (4) or placebo (2) |
| RM-718 (Cohort B3) | EXPERIMENTAL | Multiple ascending doses of RM-718 (4) or placebo (2) |
| RM-718 (Cohort B4) | EXPERIMENTAL | Multiple ascending doses of RM-718 (4) or placebo (2) |
| RM-718 (Cohort B5) | EXPERIMENTAL | Multiple ascending doses of RM-718 (4) or placebo (2) |
| RM-718 (Cohort B6) | EXPERIMENTAL | Multiple ascending doses of RM-718 (4) or placebo (2) |
| RM-718 (Cohort C1) | EXPERIMENTAL | Multiple ascending doses of RM-718 (30) |
| RM-718 (Cohort D1) | EXPERIMENTAL | Multiple ascending doses of RM-718 (up to 30) |
| Name | Type | Description |
|---|---|---|
| Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) | DRUG | Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort) |
| Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) | DRUG | Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts) |
| Part C: RM-718 | DRUG | Multiple ascending doses of RM-718 |
| Part D: RM-718 | DRUG | Multiple ascending doses of RM-718 |
Key Inclusion Criteria: Parts A and B: * Male and female subjects in good health aged 18-55 years of age at Screening. * Body mass index (BMI) ≥30 kg/m2. * Subjects who are medically healthy with normal or clinically insignificant screening results. * Subjects must use a highly effective form of c...
RM-718 is an investigational small molecule being developed for hypothalamic obesity, a rare disease. It is also being studied in patients with Prader-Willi syndrome and other MC4R pathway impairments. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
RM-718 is being developed by Rhythm Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RYTM. The company is conducting a Phase 1 clinical trial of RM-718 in the United States.
RM-718 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is actively recruiting participants in the United States.
RM-718 is being studied in a Phase 1 clinical trial with the identifier NCT06239116. This trial is titled 'A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment' and is recruiting 150 participants aged 12 years and older in the United States.
Yes, RM-718 is being studied in healthy volunteers as part of its Phase 1 clinical trial. The trial also includes patients with hypothalamic obesity, Prader-Willi syndrome, and other MC4R pathway impairments. The study is randomized, double-blind, and controlled.